Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CD19 CAR-T cells (Shanghai First Song Biotechnology)
- Development stage
- Unknown
- Lead developer
- Shanghai First Song Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 CAR-T cells (Shanghai First Song Biotechnology) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen. Developed by Shanghai First Song Biotechnology Co., LTD, this therapy is designed to treat relapsed or refractory B-cell malignancies, including B-cell lymphoma and leukemia. The treatment process involves collecting a patient's peripheral blood mononuclear cells (PBMCs), which are then genetically engineered to express a CAR specific for CD19, a protein widely expressed on the surface of B-cell lineage cells. Following lymphodepleting chemotherapy (typically with fludarabine and cyclophosphamide), the engineered cells are re-infused into the patient. Once infused, the CAR-T cells recognize and eliminate CD19-expressing malignant B cells through direct cell-mediated cytotoxicity and the release of inflammatory cytokines.
- Other names
- Anti-CD19-CAR-T cellsAnti-CD-19-CAR-T cellsAnti-CD 19-CAR-T cells
02
Targets
Beyond the preview
Go deeper on Anti-CD19 CAR-T cells (Shanghai First Song Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CD19 CAR-T cells (Shanghai First Song Biotechnology).